SLN — Silence Therapeutics plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1479615 ·
United Kingdom
Last close
$19.80
Market Cap
$1.23B
52W High
$19.86
52W Low
$4.19
ADV30
4,197,261
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | -14,224,000 | -12,426,000 | 281,498,000 | 247,659,000 | 66,477,000 |
| Jun 2026 | 0 | 0 | -13,865,000 | -12,268,000 | 106,412,000 | 72,054,000 | 67,941,000 |
| Mar 2026 | 422,000 | 411,000 | -15,737,000 | -14,957,000 | 115,123,000 | 5,657,000 | 65,721,000 |
| Dec 2025 | 34,000 | 22,000 | -12,461,000 | -11,770,000 | 131,442,000 | 11,277,000 | 69,138,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-42,263,000
Investing CF
$72,891,000
Financing CF
$2,000
CapEx
$-55,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.62
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-589,632,000
Inventory
—
Receivables
$9,292,000
ST Investments
$0
EBIT TTM
$-68,307,000
Pretax Income TTM
$-59,951,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$615,000
EBITDA
$-63,942,000
Free Cash Flow
$-23,567,624
Enterprise Value
$864,959,616
Total Cash
$72,054,000
Total Debt
$112,000
Shares Out
62,203,024
Trailing EPS
$-1.29
Book Value
$1.32
ROE
-90.4%
ROA
-29.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 559,000 | -89,753,000 | -88,612,000 | 131,442,000 | 69,138,000 | 62,304,000 | -62,271,000 |
| Dec 2024 | 43,258,000 | -63,319,000 | -45,309,000 | 202,635,000 | 68,612,000 | 134,023,000 | -67,640,000 |
| Dec 2023 | 31,643,000 | -64,383,000 | -54,228,000 | 119,448,000 | 97,455,000 | 21,993,000 | -49,462,000 |
| Dec 2022 | 21,655,000 | -61,040,000 | -50,334,000 | 130,096,453 | 103,384,928 | 26,711,525 | -57,044,000 |
TTM Snapshot
Revenues TTM
$615,000
NetIncome TTM
$-59,953,000
OpCashFlow TTM
—
Assets (Latest)
$106,412,000
Forward EPS
$-0.38
Max Pain — expiry 2027-01-15
max pain strike: $17.50 · spot: $19.82 · call oi: 21,142 · put oi: 8,957
Expected Move to 2027-01-15:
±$0.36
(1.82%) —
implied range
$19.46 –
$20.18
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KARD | Kardigan, Inc. | $1.23B | $13.19 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.23B | $13.14 | — |
| NKTR | NEKTAR THERAPEUTICS | $1.23B | $35.91 | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.24B | $29.10 | — |
| AVLN | Avalyn Pharma Inc. | $1.24B | $27.92 | — |
News headlines (Yahoo Finance, 1h cache)
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
2026-11-12 13:00 · Yahoo
Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
2026-11-04 14:00 · Yahoo
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
2026-10-20 12:59 · Yahoo
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
2026-10-20 12:55 · Yahoo
Is Silence Therapeutics (NasdaqGM:SLN) Reasonable Near Its $20 Deal Price?
2026-10-20 01:09 · Yahoo
Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%
2026-10-19 23:41 · Yahoo
Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%
2026-10-19 16:08 · Yahoo
Silence Therapeutics jumps 59% on Merck takeover
2026-10-19 15:20 · Yahoo
Silence Therapeutics stock soars 125% on Merck acquisition
2026-10-19 13:56 · Yahoo
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
2026-10-19 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.